A Phase 1, Multicenter, Open-Label Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Preliminary Efficacy Of TAB006, As Monotherapy And In Combination With Toripalimab, In Patients With Previously Treated, Advanced Malignancies